Faecal analysis and plasma complement factor 3c levels at admission for an acute attack of ulcerative colitis are predictive of the need for colectomy

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 3, 2014, Pages 295-300

  Pagoldh, Maria ^a   Lange, Stefan ^b   Jennische, Eva ^b   Almer, Sven ^c   Boström, Elisabeth A ^c   Eriksson, Anders ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytokines; Inflammation; Predictive marker

Indexed keywords

ACUTE DISEASE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; COLECTOMY; COLITIS, ULCERATIVE; COLONOSCOPY; COMPLEMENT C3C; DEFECATION; FECES; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; YOUNG ADULT;

EID: 84895072917     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000042     Document Type: Article

References (33)

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713-1725.
2. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910.
3. Carbonnel F, Gargouri D, Lémann M, Beaugerie L, Cattan S, Cosnes J, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-279.
4. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915.
5. Andersson P, Söderholm JD. Surgery in ulcerative colitis: indication and timing. Dig Dis 2009; 27: 335-340.
6. Da Luz Moreira A, Kiran RP, Lavery I. Clinical outcomes of ileorectal anastomosis for ulcerative colitis. Br J Surg 2010; 97: 65-69.
7. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-440.
8. Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997; 32: 1005-1012.
9. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
10. Lindgren SC, Flood LM, Kilander AF, Löfberg R, Persson TB, Sjödahl RI. Early predictors of glucocorticosteroid failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-835.
11. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 97-106.
12. Seo M, Okada M, Yao T, Matake H, Maeda K. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002; 37: 29-34.
13. Eriksson A, Heimtun E. Does daily fecal volume predict the clinical outcome of the acute flare of extensive ulcerative colitis in terms of need for acute colectomy? Inflamm Bowel Dis 2005; 11: 418-419.
14. Halstensen TS, Molnes TE, Garred P, Fausa O, Brandtzaeg P. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 1990; 98: 1264-1271.
15. Ueki T, Mizuno M, Uesu T, Kiso T, Nasu J, Inaba T. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol 1996; 104: 286-292.
16. Wende E, Laudeley R, Bleich A, Bleich E, Wetsel RA, Glage S, et al. The complement anaphylatoxin C3a receptor (C3aR) contributes to the inflammatory response in dextran sulfate sodium (DSS)-induced colitis in mice. PLoS One 2013; 8:e62257.
17. Schepp-Berglind J, Atkinson C, Elvington M, Qiao F, Mannon P, Tomlinson S. Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol 2012; 188: 6309-6318.
18. Palarasah Y, Skjodt K, Brandt J, Teisner B, Koch C, Vitved L, et al. Generation of a C3c specific monoclonal antibody and assessment of C3c as a putative inflammatory marker derived from complement factor C3. J Immunol Methods 2010; 362: 142-150.
19. Johansson E, Al-Olama M, Hansson HA, Lange S, Jennische E. Diet-induced antisecretory factor prevents intracranial hypertension in a dosagedependent manner. Br J Nutr 2013; 109: 2247-2252.
20. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-521.
21. Biesiada G, Czepiel J, Ptak-Belowska A, Targosz A, Krzysiek-Maczka G, Strzalka M, et al. Expression and release of leptin and proinflammatory cytokines in patients with ulcerative colitis and infectious diarrhea. J Physiol Pharmacol 2012; 63: 471-481.
22. Ohman L, Dahlén R, Isaksson S, Sjöling A,Wick MJ, Sjövall H, et al. Serum IL-17A in newly diagnosed treatment-naïve patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease. Inflamm Bowel Dis 2013; 19: 2433-2439.
23. Lange S, Lönnroth I. The antisecretory factor: synthesis, anatomical and cellular distribution, and biological action in experimental and clinical studies. Int Rev Cytol 2001; 210: 39-75.
24. Björck S, Bosaeus I, Ek E, Jennische E, Lönnroth I, Johansson E, et al. Food induced stimulation of the antisecretory factor can improve symptoms in human inflammatory bowel disease: a study of a concept. Gut 2000; 46: 824-829.
25. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomised study. N Engl J Med 1987; 317: 1625-1629.
26. Johansson E, Lönnroth I, Jonson I, Lange S, Jennische E. Development of monoclonal antibodies for detection of antisecretory factor activity in human plasma. J Immunol Methods 2009; 342: 64-70.
27. Good P. Permutation, parametric and bootstrap tests of hypotheses. 3rd ed. New York: Springer; 2005.
28. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-1087.
29. Bernal I, Mañosa M, Domènech E, Garcia-Planella E, Navarro M, Lorenzo- Zúñiga V, et al. Predictors of clinical response to systemic steroids in active ulcerative colitis. Dig Dis Sci 2006; 51: 1434-1438.
30. Turner D,Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-110.
31. Travis SPL, Satsangi J, Lémann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameter and currently available biomarkers. Gut 2011; 60: 3-9.
32. Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F,Wittmann T. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients. J Gastrointestin Liver Dis 2011; 20: 359-363.
33. Pagoldh M, Hultgren E, Arnell P, Eriksson A. Hyperbaric oxygen therapy does not improve the effects of standardised treatment in a severe attack of ulcerative colitis: a prospective randomised study. Scand J Gastroenterol 2013; 48:1033-1040.